General Biologicals Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

T.C. Lin

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	no data
Proprietà del CEO	n/a
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	Nessun dato

Aggiornamenti recenti sulla gestione

Recent updates

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

Feb 05

AMMINISTRATORE DELEGATO

T.C. Lin

no data

Mandato

Mr. T.C. Lin serves as Chairman and Chief Executive Officer at General Biologicals Corporation.

General Biologicals Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

Less than half of directors are independent

Less than half of directors are independent

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

Recent updates

New major risk - Financial position

Full year 2023 earnings released: NT$3.32 loss per share (vs NT$0.89 loss in FY 2022)

General Biologicals Corporation, Annual General Meeting, Jun 27, 2024

New minor risk - Financial data availability

New major risk - Share price stability

New minor risk - Share price stability

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Full year 2021 earnings released: EPS: NT$0.74 (vs NT$1.18 in FY 2020)

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First half 2021 earnings released: EPS NT$0.88 (vs NT$0.053 loss in 1H 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS NT$1.18 (vs NT$0.99 loss in FY 2019)

General Biologicals Corporation, Annual General Meeting, Jun 17, 2021

New 90-day low: NT$43.00

Shareholders of General Biologicals (GTSM:4117) Must Be Delighted With Their 340% Total Return

New 90-day low: NT$44.00

New 90-day low: NT$55.60

General Biologicals Corporation (GTSM:4117) completed the acquisition of additional 77% stake in Pacgen Life Science Corporation (TSXV:PBS).

New 90-day low: NT$70.50

New 90-day low - NT$99.00

First half earnings released

General Biologicals Corporation announced that it has received TWD 77.623729 million in funding from Hong Kong Chlitina International Limited

AMMINISTRATORE DELEGATO

Mandato